- Home
- NCSM vs PRLD Comparison
NCSM vs PRLD Comparison
Compare NCSM & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCSM
- PRLD
- Stock Information
- Founded
- NCSM 2006
- PRLD 2016
- Country
- NCSM United States
- PRLD United States
- Employees
- NCSM N/A
- PRLD N/A
- Industry
- NCSM Oilfield Services/Equipment
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- NCSM Energy
- PRLD Health Care
- Exchange
- NCSM Nasdaq
- PRLD Nasdaq
- Market Cap
- NCSM 76.3M
- PRLD 69.1M
- IPO Year
- NCSM 2017
- PRLD 2020
- Fundamental
- Price
- NCSM $36.70
- PRLD $1.59
- Analyst Decision
- NCSM
- PRLD Strong Buy
- Analyst Count
- NCSM 0
- PRLD 3
- Target Price
- NCSM N/A
- PRLD $4.00
- AVG Volume (30 Days)
- NCSM 13.5K
- PRLD 245.1K
- Earning Date
- NCSM 10-29-2025
- PRLD 10-31-2025
- Dividend Yield
- NCSM N/A
- PRLD N/A
- EPS Growth
- NCSM N/A
- PRLD N/A
- EPS
- NCSM 4.53
- PRLD N/A
- Revenue
- NCSM $178,000,000.00
- PRLD $7,000,000.00
- Revenue This Year
- NCSM $11.91
- PRLD N/A
- Revenue Next Year
- NCSM $7.63
- PRLD N/A
- P/E Ratio
- NCSM $8.09
- PRLD N/A
- Revenue Growth
- NCSM 16.49
- PRLD N/A
- 52 Week Low
- NCSM $17.30
- PRLD $0.61
- 52 Week High
- NCSM $53.69
- PRLD $1.91
- Technical
- Relative Strength Index (RSI)
- NCSM 36.87
- PRLD 58.19
- Support Level
- NCSM $38.71
- PRLD $1.47
- Resistance Level
- NCSM $42.88
- PRLD $1.72
- Average True Range (ATR)
- NCSM 2.65
- PRLD 0.16
- MACD
- NCSM -0.48
- PRLD 0.01
- Stochastic Oscillator
- NCSM 19.59
- PRLD 76.79
About NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. It sell products and services in North America and in selected international markets.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.